Terms: = Ovarian cancer AND DDX6, P54, 1656, ENSG00000110367, HLR2, P26196, RCK, FLJ36338
12 results:
1. A Multi-Faceted Analysis Showing
Balcerak A; Szafron LA; Rubel T; Swiderska B; Bonna AM; Konarzewska M; Sołtyszewski I; Kupryjanczyk J; Szafron LM
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673965
[No Abstract] [Full Text] [Related]
2. CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer.
Shao D; Zhou H; Yu H; Zhu X
Medicine (Baltimore); 2024 Jan; 103(3):e36891. PubMed ID: 38241595
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties.
Lucà R; Assenza MR; Maiullari F; Pieroni L; Maiullari S; Federici G; Marini F; Rizzi R; Urbani A; Soddu S; Moretti F
Cell Death Dis; 2021 May; 12(6):558. PubMed ID: 34052831
[TBL] [Abstract] [Full Text] [Related]
4. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
Pellarin I; Dall'Acqua A; Gambelli A; Pellizzari I; D'Andrea S; Sonego M; Lorenzon I; Schiappacassi M; Belletti B; Baldassarre G
Oncogene; 2020 May; 39(22):4390-4403. PubMed ID: 32332923
[TBL] [Abstract] [Full Text] [Related]
5. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract] [Full Text] [Related]
6. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients.
Zhao M; Li S; Zhou L; Shen Q; Zhu H; Zhu X
Life Sci; 2018 Feb; 194():34-39. PubMed ID: 29247747
[TBL] [Abstract] [Full Text] [Related]
8. DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome.
Liu J; Li T; Liu XL
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1206-1213. PubMed ID: 28387912
[TBL] [Abstract] [Full Text] [Related]
9. Target specificity of 188Re-labeled B27.1 monoclonal antibodies to ovarian cancer cells in vivo.
Palakurthi S; Wilson J; McQuarrie SA; Suresh MR; Mercer JR; Miller GG
In Vivo; 2008; 22(3):321-6. PubMed ID: 18610743
[TBL] [Abstract] [Full Text] [Related]
10. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract] [Full Text] [Related]
11. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.
van Niekerk CC; Boerman OC; Ramaekers FC; Poels LG
Am J Pathol; 1991 Feb; 138(2):455-63. PubMed ID: 1992770
[TBL] [Abstract] [Full Text] [Related]
12. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.
Ramaekers F; van Niekerk C; Poels L; Schaafsma E; Huijsmans A; Robben H; Schaart G; Vooijs P
Am J Pathol; 1990 Mar; 136(3):641-55. PubMed ID: 1690512
[TBL] [Abstract] [Full Text] [Related]
